Turtle Creek Wealth Advisors’s Regeneron Pharmaceuticals REGN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$211K Sell
339
-115
-25% -$78.3K 0.01% 441
2026
Q1
$351K Buy
454
+70
+18% +$53.6K 0.03% 294
2025
Q4
$296K Buy
+384
New +$261K 0.02% 302
2024
Q1
Sell
-104
Closed -$91.3K 678
2023
Q4
$91.3K Buy
+104
New +$85.6K 0.03% 208

Other funds holding REGN

Turtle Creek Wealth Advisors's REGN Position: Q2 2026 in Review

Turtle Creek Wealth Advisors reduced its Regeneron Pharmaceuticals (REGN) stake by 25% in Q2 2026, selling an estimated $78.3K and leaving 339 shares worth $211K. The position accounts for 0.01% of the portfolio, ranked #441.

Turtle Creek Wealth Advisors first reported a position in REGN in Q4 2023 and has held it in 4 quarters since. The position peaked at $351K in Q1 2026. 1,335 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • Turtle Creek Wealth Advisors held 339 shares of Regeneron Pharmaceuticals worth $211K as of Q2 2026.
  • Turtle Creek Wealth Advisors sold 115 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $78.3K.
  • Regeneron Pharmaceuticals made up 0.01% of Turtle Creek Wealth Advisors's portfolio in Q2 2026, its #441 holding.
  • Turtle Creek Wealth Advisors first reported a position in Regeneron Pharmaceuticals in Q4 2023 and has held it in 4 quarters since.
  • Turtle Creek Wealth Advisors's Regeneron Pharmaceuticals position peaked at $351K in Q1 2026.
  • 1,335 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Turtle Creek Wealth Advisors's 13F filing for Q2 2026, filed 27 Jul 2026.